Developmental Research Program 1

项目总结 淋巴瘤孢子发育研究计划(DRP)的目标是支持创新 翻译研究项目，可能在未来发展为完整的项目。为了实现这一目标， DRP将征集在淋巴瘤和慢性淋巴细胞方面具有翻译潜力的新项目的提交 白血病(CLL)。该项目将由导演马尔科姆·布伦纳博士和玛格丽特·古德尔博士领导，他们 继续担任DRP领导人和新的联合领导人George Carrum博士，他带来了临床专业知识和 致力于增加DRP获奖者的多样性。候选项目将由一个小组进行审查 凭借翻译研究方面的专业知识和最有希望的提案，将被选为支持对象。我们的 每个被支持的项目的目标是要么发展成一个完整的孢子项目，要么得到安全的同行评审 作为一个独立的项目提供资金。我们将继续实现这一目标，充分吸收 发展项目进入孢子，使他们能够利用孢子的专业知识 调查人员正在将他们的项目从替补席上翻译到床边。 在过去的四年里，我们的淋巴瘤孢子DRP通过以下方式支持了9个项目的广泛投资组合 来自贝勒医学院内五个不同部门和中心的不同调查人员 与德克萨斯医疗中心的其他机构一样(德克萨斯农工大学和莱斯大学各获一项奖项)和 全国(莫菲特癌症中心获得一项奖项)。五名女性和两名代表性不足的少数族裔调查人员 在最近的资助期内领导了九个DRP项目，并已被利用来 从45万美元的初始投资中获得865万美元的同行审查资金。长期跟踪调查 在我们孢子的前两个周期中资助的28个项目显示了46种出版物被引用超过 4,300倍和超过1,840万美元的同行审查资金，来自 我们的DRP。在与管理核心的合作下，DRP主管将继续使用该计划来 测试和开发治疗淋巴瘤和慢性淋巴细胞性白血病的新策略，并将收集数据进行评估 DRP计划的成功，包括寻求内部和外部的反馈和建议 顾问委员会。

PROJECT SUMMARY The goal of the Lymphoma SPORE Developmental Research Program (DRP) is to support innovative translational research projects that may in the future develop into full projects. To achieve this objective, the DRP will solicit submission of novel projects with translational potential in lymphoma and chronic lymphocytic leukemia (CLL). The program will be led by directors Drs. Malcolm Brenner and Margaret Goodell, who continue as DRP leaders, and new co-leader Dr George Carrum who brings with him clinical expertise and a commitment to increasing diversity among DRP awardees. Candidate projects will be reviewed by a panel with expertise in translational research and the most promising proposals will be selected for support. Our goal for each supported project is that it will either develop into a full SPORE project or secure peer-reviewed funding as an independent project. We will continue to achieve this goal by fully incorporating the leaders of developmental projects into the SPORE, enabling them to take advantage of the expertise of SPORE investigators in translating their project from the bench to bedside. In the last four years, our Lymphoma SPORE DRP has supported a broad portfolio of 9 projects by diverse investigators from five different Departments and Centers within Baylor College of Medicine as well as other institutions in the Texas Medical Center (one award to Texas A&M and one to Rice University) and nationally (one award to Moffitt Cancer Center). Five female and two underrepresented minority investigators have led the nine DRP projects supported in most recent funding period and have already been leveraged to obtain $8.65 million in peer-reviewed funding from an initial investment of $450,000. Long-term follow up of the 28 projects funded in the first two cycles of our SPORE shows 46 publications that have been cited over 4,300 times and over $18.4 million dollars in peer-reviewed funding from an investment of $1.4 million through our DRP. In collaboration with the Administrative Core, the DRP directors will continue to use this program to test and develop novel strategies for the treatment of lymphoma and CLL, and will also collect data to evaluate the success of the DRP program, including seeking the feedback and advice of our internal and external advisory boards.